A former circus performer has won the right to bring historical sexual harassment and victimisation claims against Circus Oz and its chairman Nick Yates.
Law firm Maddocks has bolstered its corporate practice with the addition of two senior mergers and acquisitions specialists, nabbed from Lander & Rogers and Herbert Smith Freehills.
As parliament weighs the latest Morrison government crackdown on class actions, the Federal Court’s chief judge has warned of “an ever present danger” of maligning the regime.
Forum Finance director Vince Tesoriero has lost a battle to stop receivers from selling luxury properties in which he and Bill Papas hold a stake pending the outcome of Westpac’s fraud case against him.
Bristol-Myers Squibb has agreed to open up its subsidised treatment program for stage IV melanoma patients to individuals who have been treated with drugs made by its competitors to settle a misuse of market power lawsuit brought by rival Merck Sharpe & Dohme.
Lander & Rogers has recruited four leading corporate lawyers from KPMG Law, including highly-regarded partner David Morris, as part of the law firm’s aggressive growth strategy.
The first order allowing plaintiffs lawyers to take a cut of the proceeds of a class action will guarantee group members in a case against G8 Education at least 72.5 per cent of any recoveries — a notably higher percentage than the minimum legislated by a controversial bill before federal parliament.
Macpherson Kelley is headed for trial next week in a case that alleges the law firm bungled the execution of a 10-year lease agreement with Shell for a service station in Melbourne, giving the energy giant an extra 320 square metres equating to $2.5 million in lost rent for its landlord client.
The parties in a class action accusing a Commonwealth Bank of Australia unit of breaching its superannuation trustee duties want the matter to be heard in person and are willing to foot the bill for the judge to travel to Sydney to make it happen.
IP Australia has quashed an extension for a patent covering a Bayer oral contraceptive, saying the extension should have been calculated based on a drug that was included on the Australian Register of Therapeutic Goods at an earlier date.